Truist initiated coverage of Curis with a Buy rating and $26 price target. Emavusertib “works” in AML/MDS and lymphoma and its largest opportunity is CLL where BTKs are the standard of care, the analyst tells investors. Phase 1/2 data in 2024 “should show CRIS is a potential take-out target because it is in big pharma’s best interest to develop the drug early,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRIS: